JusticeItaly Official institution
Italy revokes marketing authorization for Bortezomib Mylan at holder's request
Italy's medicines agency, AIFA, has revoked the marketing permission for the human medicine Bortezomib Mylan. The company that held the permission gave it up, which led to the revocation, and the official notice carries reference 26A05659.
This summary was generated by AI; the official source prevails.
What does it mean?
A medicine called Bortezomib Mylan can no longer be sold in Italy under its existing permit. The company that held that permit asked to give it up, so the approval is cancelled.
Who is affected?
Patients and pharmacies that use or supply Bortezomib Mylan in Italy.
What changes?
Bortezomib Mylan was previously authorized for sale in Italy; it is no longer authorized after the revocation.